Accretion Nutraveda IPO Details
The key details of Accretion Nutraveda’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹24.77 Cr |
| Price Range | ₹122 - ₹129 |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | BSE |
| Minimum Quantity | 2,000 |
| Investment (cut-off price) | ₹2,58,000 |
| Pre IPO Promotor Holding | 100% |
| Post IPO Promotor Holding | 73.48% |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Accretion Nutraveda IPO Timelines
The IPO process for Accretion Nutraveda includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
28/01/2026
Start Date30/01/2026
End Date03/02/2026
Refund Initiation03/02/2026
Credit of Shares to Demat Ac04/02/2026
Listing DateAccretion Nutraveda IPO Lot Size
The Accretion Nutraveda IPO has a fixed lot size of 1,000 shares, at an upper price band of ₹129 per share. For retail investors, the minimum and maximum application is 2,000 shares (2 lots) amounting to ₹2,58,000. For Small HNI (S-HNI) investors, the minimum application is 3,000 shares (3 lots) worth ₹3,87,000, while the maximum is 7,000 shares (7 lots) amounting to ₹9,03,000. Big HNI (B-HNI) investors need to apply for at least 8,000 shares (8 lots), totaling ₹10,32,000.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 | 2000 | ₹2,58,000 |
| Retail Maximum | 2 | 2000 | ₹2,58,000 |
| S-HNI Minimum | 3 | 3000 | ₹3,87,000 |
| S-HNI Maximum | 7 | 7000 | ₹9,03,000 |
| B-HNI Minimum | 8 | 8000 | ₹10,32,000 |
Accretion Nutraveda IPO Subscription Status
The subscription status for Accretion Nutraveda IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 1.01x | 2.08x | 2.19x | -- | 1.83x |
IPO Performance on Listing Day
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹ | ₹ | ₹ | ₹ |
Accretion Nutraveda IPO Company Financials
Accretion Nutraveda reports robust performance in FY2025 with Total Income of ₹16.06 crores, managing expenses at ₹12.87 crores, and achieving a strong PAT (Profit After Tax) of ₹2.61 crores, demonstrating significant growth potential ahead of its public offering.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2023 | ₹3.07 | ₹2.78 | ₹0.28 |
| FY 2024 | ₹5.20 | ₹4.28 | ₹0.82 |
| FY 2025 | ₹16.06 | ₹12.87 | ₹2.61 |
About Company
Incorporated in 2021, Accretion Nutraveda is engaged in manufacturing Ayurvedic and nutraceutical products across multiple dosage forms including tablets, capsules, oral liquids, powders, oils, and external applications such as balms, creams, and gels. Operations are structured as a Contract Development and Manufacturing Organization serving domestic markets and international destinations including Sri Lanka, Singapore, and the USA, with formulations integrating classical Ayurvedic knowledge and modern nutraceutical science for areas such as liver care, women’s health, bone and joint support, cognitive wellness, and respiratory health.
Business activities include domestic sales and merchant exports on a loan license basis contributing 96.62 percent of total revenue in FY 2024 25, along with direct exports contributing 38 percent and demonstrating consistent growth. Manufacturing is carried out at a Gujarat facility spanning approximately 10,763 square feet and featuring advanced infrastructure with multiple air handling units, segregated processing zones, and quality control systems. The facility holds GMP, WHO GMP, FSSC 22000, ISO 9001 2015, ISO 45001 2018, and Halal certifications along with an FSSAI license.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2021 | Healthcare | Mayur Sojitra |
Know Before Investing
Accretion Nutraveda IPO Strengths
- Accretion Nutraveda produces diverse dosage forms including tablets, capsules, powders, oils, balms, and gels blending classical Ayurveda with modern nutraceutical science for treatments in liver care, women’s health, joint support, and respiratory wellness.
- WHO-GMP, ISO, FSSAI, Halal, and Ayush compliance ensures global standards and market access across 20+ countries including Sri Lanka, Singapore, and USA.
- Modern 10,763 sq. ft. Gujarat facility supports end-to-end manufacturing from granulation and tableting to blister packaging and stability testing with dedicated microbiology labs.
- Covers digestive, respiratory, gynaecological, liver, skin/hair, baby care, and general wellness categories, reducing dependency on single product lines.
- CDMO model serves corporate clients and private labels with custom formulations, providing recurring revenue and scalability without heavy brand marketing costs.
- Air handling units, effluent treatment, dispensing booths, and separate storage ensure contamination-free production meeting international pharmacopoeia standards.
Accretion Nutraveda IPO Risks
- Depends on standardised botanical extracts exposes supply chain to agricultural yield variations, adulteration risks, and pricing volatility.
- Faces Himalaya, Dabur, Patanjali, and global players like Herbalife competing on brand trust, distribution, and clinical claims.
- Ayurvedic claims, nutraceutical labelling, and export certifications demand continuous investment amid evolving AYUSH/FSSAI guidelines.
- Dependence on corporate/private label clients creates vulnerability to order shifts, contract renegotiations, or client insourcing.
- Herbal formulations face potency degradation risks requiring sophisticated stability chambers and validated storage conditions.
- Inventory-heavy model with herbal raw materials, work-in-progress batches, and client credit periods strains cash conversion cycles.
Swot Analysis for Accretion Nutraveda IPO
Strengths
CDMO Manufacturing Expertise, Ayurvedic-Nutra Integration, Advanced Infrastructure
Weaknesses
Loan License Dependence, Geographic Concentration, Customer Concentration
Opportunities
Nutraceutical Market Explosion, Export Acceleration, Ayurvedic Globalisation
Threats
Raw Material Volatility, Regulatory Evolution, In-House Manufacturing Shift
Company Details
Accretion Nutraveda Ltd.
27 Xcelon Industrial Park-1, Vasna-Chacharwadi, Ta – Sanand, Ahmedabad, Gujarat, 382213
Phone: +91- 9904366177
Email: compliance@accretionnutraveda.com
Website: http://www.accretionnutraveda.com/
IPO Registar Details
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: apl.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/
FAQs
The key objectives of Accretion Nutraveda SME IPO are:
- Purchase of Machineries for Automation in existing Manufacturing unit
- Purchase of Machineries for New Manufacturing Setup
- Funding working capital requirements of the company
- General corporate purposes
Sobhagya Capital Options Pvt. Ltd. is the book-running lead managers for the Accretion Nutraveda IPO.
Accretion Nutraveda’s growth potential is supported by India’s nutraceutical market expanding over 20 percent annually, rising preventive healthcare adoption, and strong e-commerce penetration. Clean-label, science-backed positioning, product diversification into functional foods, and subscription-led recurring revenue models provide scalable growth avenues if execution remains disciplined.
The issue price for the Accretion Nutraveda IPO is set between ₹122 to ₹129 per share.
To invest in two lot of Accretion Nutraveda IPO, you need ₹2,44,000 at the lower price band (₹122 per share) or ₹2,58,000 at the upper price band (₹129 per share) for a lot size of 2,000 shares.
Accretion Nutraveda IPO shares are scheduled to be listed on the Bombay Stock Exchange (BSE) on February 4, 2025.
Refund/unblocking of funds for Accretion Nutraveda IPO will begin on February 3, 2025. ASBA/UPI blocks will be removed within 1 working day.
You can sell shares your Accretion Nutraveda IPO shares on listing day (February 4, 2025) after they are credited to your demat account. If you want to sell in the pre-open market, the timing for that session is from 9:00 AM to 9:15 AM. Otherwise, you can sell after 10:00 AM during regular trading hours.